{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:19:43Z","timestamp":1791677983898,"version":"4.3.4"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Therapies based on the combination of immune checkpoint inhibitors (ICIs) and thoracic radiotherapy (TRT) are transforming the treatment landscape of esophageal cancer. Nevertheless, the available data on adverse events (AEs) mainly stemmed from several prospective clinical trials and retrospective studies, in which, AE data are often handled and reported with less rigor than the primary beneficial outcomes of the study. Thus, we conducted a systematic review to investigate the toxicity spectrum of these novel regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We searched for all prospective clinical trials investigating the role of ICIs combined with TRT published between January 2010 and August 2022. Study articles and conference proceedings involving esophageal cancers and reporting the overall incidence or details of treatment-related AEs (trAEs) were synthesized to determine the toxicity profile of combination treatment. We compared trAEs between cancer type, programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors, and between sequential and concurrent administration of ICIs and TRT to identify potentially high-risk patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We obtained toxicity data from 14 clinical trials involving 863 patients. The pooled overall incidence was 88.97% for any-grade trAEs and 18.48% for high-grade trAEs. The three most frequent non-hematologic any-grade trAEs were reactive cutaneous capillary endothelial proliferation (RCCEP, 63.80%), esophagitis (51.54%), and fatigue (33.63%). Meanwhile, RCCEP (15.69%) was the most common non-hematologic high-grade trAE, followed by nausea (4.91%) and anorexia (3.81%). The occurrence rates of any-grade and high-grade pneumonitis were 10.82% and 0.66%, respectively. In subgroup analysis, the toxicity profiles of PD-1 and PD-L1 inhibitors were mostly similar, except for any-grade pneumonitis (15.20% vs 4.88%, p=0.03) and high-grade leukopenia (6.25% vs 59.09%, p=0.00). In addition, concurrent treatment seemed to have a higher incidence of any-grade trAEs (95.20% vs 70.85%, p=0.03) compared with sequential treatment. ESCC seems to have higher incidence of any-grade hypothyroidism (22.55% vs 8.96%, p=0.049) compared to EAC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study is the first systematic review to provide a toxicity profile of trAEs in esophageal cancer patients who received ICIs combined with TRT. Most AEs of this combination treatment are tolerable, although the incidence of any-grade trAEs was higher in the concurrent group. The difference in any-grade pneumonitis between PD-1 and PD-L1 inhibitor groups needs further validation in a large clinical trial.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1039020","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T08:25:06Z","timestamp":1668068706000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review"],"prefix":"10.3389","volume":"13","author":[{"given":"Tongzhen","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jncc.2022.02.002","article-title":"Cancer incidence and mortality in China, 2016","volume":"2","author":"Zheng","year":"2022","journal-title":"J Natl Cancer Center"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12087","article-title":"Clinical characteristics and survival of 5283 esophageal cancer patients: A multicenter study from eighteen hospitals across six regions in China","volume":"40","author":"He","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13289","article-title":"Trends in esophageal cancer survival in united states adults from 1973 to 2009: A SEER database analysis","volume":"31","author":"Njei","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.10586","article-title":"Changes in treatment and outcome of oesophageal cancer in Denmark between 2004 and 2013","volume":"104","author":"Kjaer","year":"2017","journal-title":"Br J Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.4010","article-title":"CheckMate-032: Phase I\/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A\/M) gastric cancer (GC)","volume":"34","author":"Janjigian","year":"2016","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0632","article-title":"RATIONALE 311: Tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma","volume":"17","author":"Yu","year":"2021","journal-title":"Future Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1186\/s12885-022-09573-6","article-title":"Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 study)","volume":"22","author":"Yang","year":"2022","journal-title":"BMC Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS373","article-title":"A phase 3 randomized, doubleblind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN","volume":"40","author":"Wang","year":"2022","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"New Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4045","article-title":"A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: the PERFECT trial","volume":"37","author":"Ende","year":"2019","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1971418","DOI":"10.1080\/2162402X.2021.1971418","article-title":"Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study","volume":"10","author":"Zhang","year":"2021","journal-title":"Oncoimmunology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"100807","DOI":"10.1016\/j.adro.2021.100807","article-title":"A phase 2 trial combining pembrolizumab and palliative radiation therapy in gastroesophageal cancer to augment abscopal immune responses","volume":"7","author":"Chao","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0046-7","article-title":"Safety of combining radiotherapy with immune-checkpoint inhibition","volume":"15","author":"Hwang","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00333-8","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis","volume":"22","author":"Zhou","year":"2021","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02500","article-title":"Esophagogastric cancers: Integrating immunotherapy therapy into current practice","volume":"40","author":"Patel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/emermed-2020-209567","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/emermed-2020-209567","article-title":"Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews","volume":"37","author":"Amir-Behghadami","year":"2020","journal-title":"Emerg Med J"},{"key":"B19","article-title":"Evaluation of PICO as a knowledge representation for clinical questions","volume":"2006","author":"Huang","year":"2006","journal-title":"AMIA Annu Symp Proc"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"B21","unstructured":"WellsG\n          The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses2022"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with r: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evidence Based Ment Health"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4040","article-title":"Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data","volume":"29","author":"Stijnen","year":"2010","journal-title":"Stat Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/j.ijrobp.2018.07.520","article-title":"Combination of radiation therapy and anti-PD-1 antibody SHR-1210 in treating patients with esophageal squamous cell cancer","volume":"102","author":"Jing","year":"2018","journal-title":"Int J Radiat Oncology Biology Phys"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1016\/j.ijrobp.2018.07.538","article-title":"Safety and effect of radiation therapy combined with anti-PD-1 antibody SHR-1210 as first-line treatment on patients with intolerable concurrent chemoradiotherapy esophageal cancer: A phase 1B clinical trial","volume":"102","author":"Pang","year":"2018","journal-title":"Int J Radiat Oncology Biology Phys"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.07.1773","article-title":"Safety and tolerability of neoadjuvant chemoradiotherapy combined with pembrolizumab for local advanced, resectable esophageal cancer: Preliminary results of a prospective phase IB trial","volume":"108","author":"Qi","year":"2020","journal-title":"Int J Radiat Oncology Biology Phys"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.07.238","article-title":"Safety and tolerability of neoadjuvant radiotherapy combined with anti-PD-1 antibody toripalimab for locally advanced, resectable esophageal squamous cell cancer: A prospective phase IB trial","volume":"111","author":"Sun","year":"2021","journal-title":"Int J Radiat Oncology Biology Phys"},{"key":"B31","doi-asserted-by":"publisher","first-page":"S838","DOI":"10.1016\/j.annonc.2021.08.1362","article-title":"978P a prospective study of camrelizumab monotherapy following definitive concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell cancer","volume":"32","author":"Wang","year":"2021","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4034","article-title":"Phase I\/II trial of perioperative avelumab in combination with chemoradiation (CRT) in the treatment of stage II\/III resectable esophageal and gastroesophageal junction (E\/GEJ) cancer","volume":"40","author":"Uboha","year":"2022","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"100385","DOI":"10.1016\/j.esmoop.2022.100385","article-title":"Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: A placebo-controlled, randomized, double-blind, phase II study","volume":"7","author":"Park","year":"2022","journal-title":"Esmo Open"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.736620","article-title":"A phase II trial of adjuvant durvalumab following trimodality therapy for locally advanced esophageal and gastroesophageal junction adenocarcinoma: A big ten cancer research consortium study","volume":"11","author":"Mamdani","year":"2021","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.11.039","article-title":"Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)","volume":"144","author":"Li","year":"2021","journal-title":"Eur J Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.326","article-title":"A prospective clinical trial of camrelizumab in combination with chemoradiotherapy in patients with metastatic esophageal squamous cell carcinoma","volume":"40","author":"Chen","year":"2022","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"v754","DOI":"10.1093\/annonc\/mdz065.004","article-title":"A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC)","volume":"30","author":"Lee","year":"2019","journal-title":"Ann Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.17.1623","article-title":"Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). radiation therapy oncology group","volume":"281","author":"Cooper","year":"1999","journal-title":"JAMA"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(98)00232-6","article-title":"Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern cooperative oncology group","volume":"42","author":"Smith","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2008.12.012","article-title":"A randomized phase II study of cisplatin\/5-FU concurrent chemoradiotherapy for esophageal cancer: Short-term infusion versus protracted infusion chemotherapy (KROSG0101\/JROSG021)","volume":"92","author":"Nishimura","year":"2009","journal-title":"Radiother Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3727\/096504016X14537290676865","article-title":"Clinical outcome in definitive concurrent chemoradiation with weekly paclitaxel and carboplatin for locally advanced esophageal and junctional cancer","volume":"23","author":"Noronha","year":"2016","journal-title":"Oncol Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1634\/theoncologist.2019-0931","article-title":"Weekly chemotherapy of 5-fluorouracil plus cisplatin concurrent with radiotherapy for esophageal squamous cell carcinoma patients with postoperative locoregional recurrence: Results from a phase II study","volume":"25","author":"Chen","year":"2020","journal-title":"Oncologist"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2705","article-title":"Efficacy of concurrent chemoradiotherapy with s-1 vs radiotherapy alone for older patients with esophageal cancer: A multicenter randomized phase 3 clinical trial","volume":"7","author":"Ji","year":"2021","journal-title":"JAMA Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.034","article-title":"Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus","volume":"23","author":"Stahl","year":"2005","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.7118","article-title":"Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102","volume":"25","author":"Bedenne","year":"2007","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.2373","article-title":"Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: The NEOCRTEC5010 randomized clinical trial","volume":"156","author":"Yang","year":"2021","journal-title":"JAMA Surg"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): A phase III multicenter, randomized, open-label clinical trial","volume":"36","author":"Yang","year":"2018","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.08.009","article-title":"Severe lymphopenia acquired during chemoradiotherapy for esophageal cancer: Incidence and external validation of a prediction model","volume":"163","author":"Kroese","year":"2021","journal-title":"Radiother Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01920","article-title":"Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): A multicenter, open-label, single-arm, phase II trial","volume":"38","author":"Lan","year":"2020","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1680","article-title":"A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-020-00886-2","article-title":"Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3724","article-title":"The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer","volume":"10","author":"Dreyfuss","year":"2021","journal-title":"Cancer Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1748-717X-7-64","article-title":"Determination of cytokine protein levels in oral secretions in patients undergoing radiotherapy for head and neck malignancies","volume":"7","author":"Citrin","year":"2012","journal-title":"Radiat Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-364935-5.50017-1","article-title":"Cytokines involved in pulmonary fibrosis","author":"Piguet","year":"1993","journal-title":"Int Rev Exp Pathol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.163.1.2005069","article-title":"Transforming growth factor-beta1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinase-dependent pathway","volume":"163","author":"Hashimoto","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000108","article-title":"Soluble TNF mediates the transition from pulmonary inflammation to fibrosis","volume":"1","author":"Oikonomou","year":"2006","journal-title":"PLoS One"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.01.045","article-title":"Immunological markers that predict radiation toxicity","volume":"368","author":"Sprung","year":"2015","journal-title":"Cancer Lett"},{"key":"B59","doi-asserted-by":"publisher","first-page":"R265","DOI":"10.1152\/ajpregu.00147.2017","article-title":"Th17 cells contribute to pulmonary fibrosis and inflammation during chronic kidney disease progression after acute ischemia","volume":"314","author":"Mehrotra","year":"2018","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-Small-Cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"S4082","DOI":"10.21037\/jtd.2018.09.103","article-title":"Programmed death ligand-1 inhibitors potentially carry a lower risk of pneumonitis compared with programmed death-1 inhibitors in patients with non-small cell lung cancer","volume":"10","author":"Fukuda","year":"2018","journal-title":"J Thorac Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31043","article-title":"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature","volume":"124","author":"Pillai","year":"2018","journal-title":"Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"}],"updated-by":[{"DOI":"10.3389\/fimmu.2023.1193710","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1039020\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T10:45:30Z","timestamp":1681123530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1039020\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2022.1039020"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1039020","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fimmu.2023.1193710","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]},"article-number":"1039020"}}